#ROPCA joins the major European IHI AutoPiX project to revolutionize imaging in rheumatology
We are proud to be part of the newly launched IHI AutoPiX project, a collaborative effort between European research partners, pharmaceutical companies, small and medium-sized enterprises (SMEs), and patient organizations under the Innovative Health Initiative (@IHI) public-private partnership.
The AutoPiX project aims to improve the diagnosis, treatment decisions and monitoring of major rheumatic diseases, including rheumatoid arthritis (#RA), psoriatic arthritis, and axial spondyloarthritis, by leveraging AI to make clinical imaging more interpretable to scientists, clinicians, and patients.
This five-year project has a total budget of over €20 million, funded equally by the European Union and the European Federation of Pharmaceutical Industries (@EFPIA), along with other industry partners. The initiative seeks to address critical unmet medical needs in rheumatology imaging, such as limited access to advanced techniques and gaps in precision for treatment selection. Coordinated by the @Medical University of Vienna under the leadership of @Prof. Dr. Daniel Aletaha and Assoc. Prof. @Dr. Peter Mandl, and led by @Robert Janiczek, PhD, from @Johnson & Johnson, the project will unite efforts across Europe.
As part of the consortium, we at #ROPCA are committed to contributing to this innovative project, which has the potential to provide more precise diagnoses, personalized treatment paths, and reliable assessments of treatment responses.
👉 Learn more about the project here: https://www.autopix-project.eu
